Table 1 Patients characteristics
From: Rectal-sparing type of ulcerative colitis predicts lack of response to pharmacotherapies
All patients n = 482 | RST n = 46 | non RST n = 436 | p- value | |
|---|---|---|---|---|
Gender (Male/Female) | 316/166 | 29/17 | 287/149 | 0.74 |
Age at onset of UC (years) | 35.7 ± 17.4 | 35.7 ± 18.8 | 35.7 ± 17.3 | 0.99 |
Age at initial surgery (years) | 44.6 ± 16.7 | 41.2 ± 19.3 | 44.9 ± 16.4 | 0.15 |
Disease duration (months) | 70.2 (0.2-479.7) | 31.4 (1.1-347.3) | 73.6 (0.2-479.7) | <0.01* |
Severe/Fulminant disease | 145(30.1) | 21(45.7) | 124(28.4) | 0.02* |
Total givenPSL dose (mg) | 5000 (0-200,000) | 4535 (300-47,000) | 5000 (0-200,000) | 0.76 |
Daily pre-opearative PSL dose (mg/day) | 9(0-80) | 12.5(0-80) | 7.5(0-80) | 0.38 |
Immunomodulators administration | 247(51.2) | 30(65.2) | 217(49.8) | 0.04* |
Biologics administration | 127(26.3) | 11(23.9) | 116(26.6) | 0.69 |
Surgical indication | ||||
cancer/dysplasia | 110(22.8) | 2(4.3) | 108(24.8) | <0.01* |
free perforation | 27(5.6) | 2(4.3) | 25(5.7) | |
refractory disease | 343(71.2) | 42(91.3) | 301(69.0) | |
EIMs | 2(0.4) | 0 | 2(0.4) | |
Urgent/emergent surgery | 131(27.2) | 24(52.2) | 107(24.5) | <0.01* |